High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents

BACKGROUND: Once‐daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate‐to‐severe atopic dermatitis (AD) in randomized controlled studies. OBJECTIVE: To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly u...

Descripción completa

Detalles Bibliográficos
Autores principales: Ständer, S., Bhatia, N., Gooderham, M. J., Silverberg, J. I., Thyssen, J. P., Biswas, P., DiBonaventura, M., Romero, W., Farooqui, S. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539871/
https://www.ncbi.nlm.nih.gov/pubmed/35462428
http://dx.doi.org/10.1111/jdv.18170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539871/
https://www.ncbi.nlm.nih.gov/pubmed/35462428
http://dx.doi.org/10.1111/jdv.18170

Ejemplares similares